Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trial

BackgroundMetabolic syndrome (MetS) represents a constellation of metabolic abnormalities. Perirenal fat is a type of visceral fat surrounding the kidneys and possesses distinct anatomical and physiological features. This study aims to investigate the association between perirenal fat volume (PrFV)...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Hua, Meng-Huan Li, Yu-Xuan Lou, Ke-Rui Zhang, Jia-Ming Yang, Yan-Hui Sheng, Yu-Qing Zhang, Chuan-li Cheng, Chao Zou, Ting-ting Wu, Xiang-Qing Kong, Wei Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1557701/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849715165509976064
author Yang Hua
Meng-Huan Li
Meng-Huan Li
Yu-Xuan Lou
Ke-Rui Zhang
Jia-Ming Yang
Yan-Hui Sheng
Yu-Qing Zhang
Chuan-li Cheng
Chao Zou
Ting-ting Wu
Xiang-Qing Kong
Xiang-Qing Kong
Wei Sun
Wei Sun
author_facet Yang Hua
Meng-Huan Li
Meng-Huan Li
Yu-Xuan Lou
Ke-Rui Zhang
Jia-Ming Yang
Yan-Hui Sheng
Yu-Qing Zhang
Chuan-li Cheng
Chao Zou
Ting-ting Wu
Xiang-Qing Kong
Xiang-Qing Kong
Wei Sun
Wei Sun
author_sort Yang Hua
collection DOAJ
description BackgroundMetabolic syndrome (MetS) represents a constellation of metabolic abnormalities. Perirenal fat is a type of visceral fat surrounding the kidneys and possesses distinct anatomical and physiological features. This study aims to investigate the association between perirenal fat volume (PrFV) and MetS in Chinese adults.MethodsWe conducted a post-hoc cross-sectional analysis within a multicenter, randomized clinical trial. Demographic information, anthropometric data and laboratory tests were obtained from the electronic data capture system. PrFV was assessed and measured by ultrasonography. Subcutaneous and visceral fat volume were quantified by abdominal MRI. Individuals were categorized according to PrFV tertiles, and Spearman correlation analysis was performed to investigate the correlation between PrFV and metabolic profiles. Adjusted multivariable regression models were employed to investigate the relationship of PrFV with MetS. The receiver operating characteristic curve was used to identify the value of PrFV for predicting MetS.ResultsAmong 100 enrolled subjects, the median age was 50.0 (40.0-60.0) years, and 75% were male. Spearman correlation analysis revealed significant positive correlations between PrFV and total cholesterol (r = 0.24, P = 0.02), triglycerides (r = 0.32, P = 0.001), LDL-C (r = 0.21, P = 0.04), diastolic blood pressure (r = 0.24, P = 0.02), BMI (r = 0.39, P < 0.001), waist circumference (r = 0.39, P < 0.001), and uric acid (r = 0.40, P < 0.001). In the fully-adjusted multivariable regression model, individuals in the highest tertile of PrFV exhibited a higher risk of MetS (Odds ratio = 4.48, 95% Confidence interval: 1.25-17.6). The area under the curve (AUC) of PrFV for predicting MetS was higher than subcutaneous and visceral fat volume.ConclusionIncreased PrFV was positively associated with a higher risk of MetS in Chinese adults. Perirenal fat may serve as a surrogate marker and potential therapeutic target for MetS.Clinical trial registrationhttps://clinicaltrials.gov/, identifier NCT 05049096.
format Article
id doaj-art-0dbee71782df4a0e9eb356bc6ffcd2e4
institution DOAJ
issn 1664-2392
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj-art-0dbee71782df4a0e9eb356bc6ffcd2e42025-08-20T03:13:29ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-05-011610.3389/fendo.2025.15577011557701Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trialYang Hua0Meng-Huan Li1Meng-Huan Li2Yu-Xuan Lou3Ke-Rui Zhang4Jia-Ming Yang5Yan-Hui Sheng6Yu-Qing Zhang7Chuan-li Cheng8Chao Zou9Ting-ting Wu10Xiang-Qing Kong11Xiang-Qing Kong12Wei Sun13Wei Sun14Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaDepartment of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaDepartment of Cardiology, The First Affiliated Hospital with Nanchang Medical University, Nanchang, ChinaDepartment of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaCardiovascular Research Center, The Affiliated Suzhou Hospital with Nanjing Medical University, Gusu School, Suzhou, ChinaCardiovascular Research Center, The Affiliated Suzhou Hospital with Nanjing Medical University, Gusu School, Suzhou, ChinaCardiovascular Research Center, The Affiliated Suzhou Hospital with Nanjing Medical University, Gusu School, Suzhou, ChinaDepartment of Cardiology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, ChinaPaul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, ChinaPaul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, ChinaDepartment of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaDepartment of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaCardiovascular Research Center, The Affiliated Suzhou Hospital with Nanjing Medical University, Gusu School, Suzhou, ChinaDepartment of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, ChinaCardiovascular Research Center, The Affiliated Suzhou Hospital with Nanjing Medical University, Gusu School, Suzhou, ChinaBackgroundMetabolic syndrome (MetS) represents a constellation of metabolic abnormalities. Perirenal fat is a type of visceral fat surrounding the kidneys and possesses distinct anatomical and physiological features. This study aims to investigate the association between perirenal fat volume (PrFV) and MetS in Chinese adults.MethodsWe conducted a post-hoc cross-sectional analysis within a multicenter, randomized clinical trial. Demographic information, anthropometric data and laboratory tests were obtained from the electronic data capture system. PrFV was assessed and measured by ultrasonography. Subcutaneous and visceral fat volume were quantified by abdominal MRI. Individuals were categorized according to PrFV tertiles, and Spearman correlation analysis was performed to investigate the correlation between PrFV and metabolic profiles. Adjusted multivariable regression models were employed to investigate the relationship of PrFV with MetS. The receiver operating characteristic curve was used to identify the value of PrFV for predicting MetS.ResultsAmong 100 enrolled subjects, the median age was 50.0 (40.0-60.0) years, and 75% were male. Spearman correlation analysis revealed significant positive correlations between PrFV and total cholesterol (r = 0.24, P = 0.02), triglycerides (r = 0.32, P = 0.001), LDL-C (r = 0.21, P = 0.04), diastolic blood pressure (r = 0.24, P = 0.02), BMI (r = 0.39, P < 0.001), waist circumference (r = 0.39, P < 0.001), and uric acid (r = 0.40, P < 0.001). In the fully-adjusted multivariable regression model, individuals in the highest tertile of PrFV exhibited a higher risk of MetS (Odds ratio = 4.48, 95% Confidence interval: 1.25-17.6). The area under the curve (AUC) of PrFV for predicting MetS was higher than subcutaneous and visceral fat volume.ConclusionIncreased PrFV was positively associated with a higher risk of MetS in Chinese adults. Perirenal fat may serve as a surrogate marker and potential therapeutic target for MetS.Clinical trial registrationhttps://clinicaltrials.gov/, identifier NCT 05049096.https://www.frontiersin.org/articles/10.3389/fendo.2025.1557701/fullmetabolic syndromeperirenal fatultrasonographyvisceral fatChinese population
spellingShingle Yang Hua
Meng-Huan Li
Meng-Huan Li
Yu-Xuan Lou
Ke-Rui Zhang
Jia-Ming Yang
Yan-Hui Sheng
Yu-Qing Zhang
Chuan-li Cheng
Chao Zou
Ting-ting Wu
Xiang-Qing Kong
Xiang-Qing Kong
Wei Sun
Wei Sun
Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trial
Frontiers in Endocrinology
metabolic syndrome
perirenal fat
ultrasonography
visceral fat
Chinese population
title Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trial
title_full Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trial
title_fullStr Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trial
title_full_unstemmed Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trial
title_short Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trial
title_sort perirenal fat as a potential marker and therapeutic target for metabolic syndrome insights from a multicenter randomized controlled trial
topic metabolic syndrome
perirenal fat
ultrasonography
visceral fat
Chinese population
url https://www.frontiersin.org/articles/10.3389/fendo.2025.1557701/full
work_keys_str_mv AT yanghua perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT menghuanli perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT menghuanli perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT yuxuanlou perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT keruizhang perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT jiamingyang perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT yanhuisheng perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT yuqingzhang perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT chuanlicheng perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT chaozou perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT tingtingwu perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT xiangqingkong perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT xiangqingkong perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT weisun perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial
AT weisun perirenalfatasapotentialmarkerandtherapeutictargetformetabolicsyndromeinsightsfromamulticenterrandomizedcontrolledtrial